Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASCO 2023 | Reviewing the role and efficacy of ruxolitinib in myelofibrosis ten years after its approval

Naveen Pemmaraju • 3 Jun 2023
ASCO 2023
Myelofibrosis Myeloproliferative Neoplasms Ruxolitinib

Naveen Pemmaraju, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, gives an overview of a recently published review investigating the efficacy and role of ruxolitinib in myelofibrosis (MF) ten years after its approval. This review will include topics including practical tips, long-term toxicities, and combination therapies. This interview took place at the American Society of Clinical Oncology (ASCO) 2023 Annual Congress in Chicago, IL.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Naveen Pemmaraju

1:40
TAG-AZA-VEN in the treatment of patients with newly diagnosed CD123+ AML
Naveen Pemmaraju • 11 Dec 2023
1:29
Exciting developments in the field of BPDCN
Naveen Pemmaraju • 11 Dec 2023
1:58
TRANSFORM-1: navitoclax + ruxolitinib vs placebo + ruxolitinib in patients with untreated MF
Naveen Pemmaraju • 11 Dec 2023
1:15
Exploring the evolving treatment landscape of myelofibrosis
Naveen Pemmaraju • 3 Jun 2023

Related Videos

2:05
Donor lymphocyte infusion for relapsed myelofibrosis in the post-alloSCT setting
Alex Rampotas • 16 Apr 2024
2:52
JAK inhibitor combination therapy for the treatment of myelofibrosis
Ruben Mesa • 9 Dec 2023
1:30
XPORT-MF-034: selinexor + ruxolitinib combination therapy for MF
John Mascarenhas • 10 Dec 2023
1:38
Pelabresib plus ruxolitinib for the treatment of intermediate- and high-risk myelofibrosis
John Mascarenhas • 10 Dec 2023
The content of VJHemOnc is intended for healthcare professionals